ADAPTIMMUNE THERAPEUTICS PLC's ticker is ADAP and the CUSIP is 00653A107. A total of 70 filers reported holding ADAPTIMMUNE THERAPEUTICS PLC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $802 | -42.4% | 1,027,860 | -31.8% | 0.00% | -50.0% |
| Q2 2023 | $1,393 | +600.0% | 1,506,375 | +724.5% | 0.00% | – |
| Q1 2023 | $199 | -75.7% | 182,700 | -67.4% | 0.00% | -100.0% |
| Q4 2022 | $819 | -99.9% | 560,973 | -0.9% | 0.00% | 0.0% |
| Q3 2022 | $609,000 | -29.8% | 566,232 | +11.0% | 0.00% | 0.0% |
| Q2 2022 | $867,000 | -56.1% | 510,000 | -46.9% | 0.00% | -50.0% |
| Q1 2022 | $1,977,000 | +23.3% | 959,703 | +124.4% | 0.00% | 0.0% |
| Q4 2021 | $1,604,000 | +24.1% | 427,687 | +40.9% | 0.00% | 0.0% |
| Q2 2021 | $1,293,000 | +141.2% | 303,495 | +200.5% | 0.00% | +100.0% |
| Q1 2021 | $536,000 | -88.9% | 101,000 | -88.7% | 0.00% | -80.0% |
| Q4 2020 | $4,808,000 | -54.4% | 892,095 | -32.5% | 0.01% | -54.5% |
| Q3 2020 | $10,546,000 | -38.2% | 1,321,611 | -22.5% | 0.01% | -26.7% |
| Q2 2020 | $17,071,000 | +258.6% | 1,705,411 | -2.5% | 0.02% | +200.0% |
| Q1 2020 | $4,760,000 | +170.8% | 1,749,960 | +19.4% | 0.01% | +400.0% |
| Q4 2019 | $1,758,000 | +32.5% | 1,465,143 | +66.7% | 0.00% | 0.0% |
| Q3 2019 | $1,327,000 | -33.6% | 878,759 | +76.8% | 0.00% | -50.0% |
| Q2 2019 | $1,998,000 | -41.5% | 497,100 | -37.4% | 0.00% | -33.3% |
| Q1 2019 | $3,416,000 | -5.1% | 794,500 | +26.9% | 0.00% | -25.0% |
| Q4 2018 | $3,601,000 | -74.3% | 626,300 | -39.4% | 0.00% | -71.4% |
| Q3 2018 | $14,018,000 | -53.5% | 1,033,800 | -60.4% | 0.01% | -12.5% |
| Q2 2018 | $30,122,000 | +105.4% | 2,608,107 | +99.7% | 0.02% | 0.0% |
| Q1 2018 | $14,666,000 | +120.9% | 1,306,000 | +31.4% | 0.02% | +128.6% |
| Q4 2017 | $6,640,000 | -29.8% | 994,000 | -13.9% | 0.01% | -36.4% |
| Q3 2017 | $9,460,000 | +97.0% | 1,155,100 | +8.0% | 0.01% | +83.3% |
| Q2 2017 | $4,801,000 | +11.6% | 1,069,300 | +36.9% | 0.01% | 0.0% |
| Q1 2017 | $4,302,000 | +138.6% | 780,800 | +75.4% | 0.01% | +100.0% |
| Q4 2016 | $1,803,000 | -22.2% | 445,100 | +35.4% | 0.00% | -25.0% |
| Q3 2016 | $2,317,000 | +50.3% | 328,700 | +73.7% | 0.00% | +33.3% |
| Q2 2016 | $1,542,000 | +67.6% | 189,200 | +67.1% | 0.00% | +50.0% |
| Q1 2016 | $920,000 | +160.6% | 113,200 | +286.3% | 0.00% | +100.0% |
| Q4 2015 | $353,000 | – | 29,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Syncona Portfolio Ltd | 1,377,294 | $1,501,250 | 2.44% |
| NEA Management Company, LLC | 17,079,779 | $18,616,958 | 1.29% |
| Endurant Capital Management LP | 1,660,835 | $1,810,310 | 0.93% |
| Matrix Capital Management Company, LP | 38,974,185 | $42,481,862 | 0.58% |
| Long Focus Capital Management, LLC | 5,435,439 | $5,924,629 | 0.34% |
| PFM Health Sciences, LP | 5,992,571 | $6,531,902 | 0.29% |
| Key Client Fiduciary Advisors, LLC | 321,155 | $350,059 | 0.22% |
| DAFNA Capital Management LLC | 351,064 | $382,660 | 0.12% |
| Rock Springs Capital Management LP | 2,787,845 | $3,038,751 | 0.07% |
| Baker Brothers Advisors | 9,830,877 | $10,715,656 | 0.06% |